

# Joseph Mikhael

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2236518/publications.pdf>

Version: 2024-02-01

18  
papers

1,241  
citations

840119

11  
h-index

839053

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <scp>IKEMA</scp> subgroup analysis. American Journal of Hematology, 2023, 98, .	2.0	6
2	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	1.1	2
3	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances, 2022, 6, 4506-4515.	2.5	4
4	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer Journal, 2021, 11, 89.	2.8	49
5	Real-world renal function among patients with multiple myeloma in the United States. Blood Cancer Journal, 2021, 11, 99.	2.8	3
6	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet, The, 2021, 397, 2361-2371.	6.3	177
7	Digital Health for Patients With Multiple Myeloma: An Unmet Need. JCO Clinical Cancer Informatics, 2021, 5, 1096-1105.	1.0	12
8	Treatment Options for Triple-class Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 1-7.	0.2	73
9	COVID-19 and myeloma: what are the implications for now and in the future?. British Journal of Haematology, 2020, 190, 173-178.	1.2	9
10	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia, 2020, 34, 3298-3309.	3.3	37
11	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019, 94, 1176-1184.	2.0	112
12	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood, 2019, 134, 123-133.	0.6	82
13	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 41.	2.8	80
14	Turn off the Tap! The Need for Induction Therapy for AL Amyloidosis Before Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, e1-e2.	2.0	3
15	Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer Journal, 2018, 8, 86.	2.8	16
16	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 2017, 130, 2401-2409.	0.6	403
17	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. Blood, 2016, 128, 488-488.	0.6	27
18	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146